CR20190392A - Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) - Google Patents
Compuestos moduladores del receptor de hidrocarburos de arilo (ahr)Info
- Publication number
- CR20190392A CR20190392A CR20190392A CR20190392A CR20190392A CR 20190392 A CR20190392 A CR 20190392A CR 20190392 A CR20190392 A CR 20190392A CR 20190392 A CR20190392 A CR 20190392A CR 20190392 A CR20190392 A CR 20190392A
- Authority
- CR
- Costa Rica
- Prior art keywords
- ahr
- aryl hydrocarbon
- hydrocarbon receptor
- compounds
- modulator compounds
- Prior art date
Links
- 102000003984 Aryl Hydrocarbon Receptors Human genes 0.000 title abstract 9
- 108090000448 Aryl Hydrocarbon Receptors Proteins 0.000 title abstract 9
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 239000005557 antagonist Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
La presente invención se refiere a compuestos que pueden actuar como moduladores del receptor de hidrocarburos de arilo (AhR) y, en particular, como antagonistas de AhR. La invención además se refiere al uso de los compuestos para el tratamiento y/o profilaxis de enfermedades y/o condiciones a través de la unión de dicho receptor de hidrocarburos de arilo por dichos compuestos.The present invention relates to compounds which can act as aryl hydrocarbon receptor (AhR) modulators and, in particular, as AhR antagonists. The invention further relates to the use of the compounds for the treatment and/or prophylaxis of diseases and/or conditions through binding of said aryl hydrocarbon receptor by said compounds.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17000158 | 2017-02-01 | ||
| PCT/EP2018/052542 WO2018141857A1 (en) | 2017-02-01 | 2018-02-01 | Aryl hydrocarbon receptor (ahr) modulator compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190392A true CR20190392A (es) | 2019-10-21 |
Family
ID=57960223
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190392A CR20190392A (es) | 2017-02-01 | 2018-02-01 | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10981908B2 (es) |
| EP (1) | EP3577112B1 (es) |
| JP (1) | JP6849823B2 (es) |
| KR (1) | KR102320516B1 (es) |
| CN (1) | CN110248940B (es) |
| AR (1) | AR110789A1 (es) |
| AU (1) | AU2018216957B2 (es) |
| BR (1) | BR112019015716A2 (es) |
| CA (1) | CA3050827C (es) |
| CL (1) | CL2019002108A1 (es) |
| CO (1) | CO2019007881A2 (es) |
| CR (1) | CR20190392A (es) |
| CU (1) | CU20190069A7 (es) |
| EA (1) | EA038318B1 (es) |
| EC (1) | ECSP19055169A (es) |
| ES (1) | ES2858329T3 (es) |
| IL (1) | IL268080B (es) |
| JO (1) | JOP20190175A1 (es) |
| MX (1) | MX393702B (es) |
| MY (1) | MY196831A (es) |
| NI (1) | NI201900076A (es) |
| PE (1) | PE20191478A1 (es) |
| PH (1) | PH12019550135A1 (es) |
| SG (1) | SG11201906958TA (es) |
| TW (1) | TWI752155B (es) |
| UA (1) | UA122745C2 (es) |
| UY (1) | UY37589A (es) |
| WO (1) | WO2018141857A1 (es) |
| ZA (1) | ZA201904771B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| ES2946632T7 (es) | 2018-02-06 | 2025-03-04 | Ideaya Biosciences Inc | Moduladores de AhR |
| WO2020021024A1 (en) * | 2018-07-26 | 2020-01-30 | Phenex Pharmaceuticals Ag | Substituted bicyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
| CN113454207A (zh) * | 2018-11-30 | 2021-09-28 | 细胞结构公司 | 用新型芳香族化合物扩增自然杀伤细胞和ilc3细胞 |
| WO2021148628A1 (en) * | 2020-01-23 | 2021-07-29 | Phenex Pharmaceuticals Ag | Oxalamide substituted heterocyclic compounds as modulators of the aryl hydrocarbon receptor (ahr) |
| US20230279000A1 (en) | 2020-02-26 | 2023-09-07 | Jaguahr Therapeutics Pte Ltd | Pyridopyrimidine derivatives useful in modulation of ahr signalling |
| WO2021236717A1 (en) | 2020-05-20 | 2021-11-25 | Senda Biosciences, Inc. | Fused imidazole derivatives as ahr antagonists |
| WO2021242955A1 (en) * | 2020-05-28 | 2021-12-02 | Senda Biosciences, Inc. | Fused azole heterocycles as ahr antagonists |
| ES3061465T3 (en) * | 2020-08-05 | 2026-04-06 | Saniona As | Difluoromethyl-pyridin-2-yl triazoles |
| CN114181212B (zh) * | 2020-09-15 | 2023-06-06 | 山东轩竹医药科技有限公司 | 哒嗪酮类AhR抑制剂 |
| CN114835687B (zh) * | 2021-04-02 | 2023-09-05 | 北京华森英诺生物科技有限公司 | AhR抑制剂 |
| CN115572282B (zh) * | 2021-07-05 | 2024-07-09 | 华东理工大学 | 含芳杂环结构的吡唑酰胺类化合物及其制备方法和应用 |
| WO2024076300A1 (en) | 2022-10-03 | 2024-04-11 | Jaguahr Therapeutics Pte Ltd | Compounds useful in modulation of ahr signalling |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU8225991A (en) | 1990-07-31 | 1992-03-02 | Teikoku Hormone Mfg. Co., Ltd. | 2-phenylindole derivative |
| DE69728688T2 (de) | 1996-11-19 | 2004-08-19 | Amgen Inc., Thousand Oaks | Aryl und heteroaryl substituierte kondensierte pyrrole als entzündunghemmende mittel |
| AU2003270426A1 (en) | 2002-09-12 | 2004-04-30 | Avanir Pharmaceuticals | PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION |
| US20050032869A1 (en) | 2003-07-08 | 2005-02-10 | Pharmacia Italia S.P.A. | Pyrazolyl-indole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them |
| ES2351940T3 (es) | 2005-11-18 | 2011-02-14 | F. Hoffmann-La Roche Ag | Derivados de azaindol-2-carboxamida. |
| US8563573B2 (en) * | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| JP5819305B2 (ja) | 2009-10-13 | 2015-11-24 | リガンド・ファーマシューティカルズ・インコーポレイテッド | 造血成長因子模倣小分子化合物およびそれらの使用 |
| EP3689347A1 (en) * | 2009-11-02 | 2020-08-05 | Ariagen, Inc. | Ite for cancer intervention and eradication |
| US20130338201A1 (en) * | 2009-11-02 | 2013-12-19 | Ahr Pharmaceuticals, Inc. | Method of Cancer Treatment with 2-(1H-Indole-3-Carbonyl)-Thiazole-4-Carboxylic Acid Methyl Ester |
| PL2531501T3 (pl) | 2010-02-03 | 2014-05-30 | Takeda Pharmaceuticals Co | Inhibitory kinazy 1 regulującej sygnał apoptotyczny |
| US8410117B2 (en) | 2010-03-26 | 2013-04-02 | Hoffmann-La Roche Inc. | Imidazopyrimidine derivatives |
| TWI619713B (zh) | 2010-04-21 | 2018-04-01 | 普雷辛肯公司 | 用於激酶調節的化合物和方法及其適應症 |
| BR112013002079B1 (pt) | 2010-07-27 | 2021-09-14 | Trustees Of Boston University | Modificadores do receptor de aril hidrocarboneto (ahr) como novos terapêuticos contra o câncer |
| GB201104267D0 (en) | 2011-03-14 | 2011-04-27 | Cancer Rec Tech Ltd | Pyrrolopyridineamino derivatives |
| CA2888369A1 (en) | 2012-10-17 | 2014-04-24 | F. Hoffmann-La Roche Ag | 6-aminoindole derivatives as trp channel antagonists |
| EP2935248B1 (en) | 2012-12-21 | 2018-02-28 | Plexxikon Inc. | Compounds and methods for kinase modulation, and indications therefor |
| TWI674260B (zh) | 2017-02-01 | 2019-10-11 | 德商菲尼克斯製藥股份有限公司 | 芳基烴受體(AhR)調節劑化合物 |
| TWI752155B (zh) | 2017-02-01 | 2022-01-11 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
| TW201835070A (zh) | 2017-02-21 | 2018-10-01 | 德商菲尼克斯製藥股份有限公司 | 芳香烴受體(AhR)調節劑化合物 |
-
2018
- 2018-01-26 TW TW107102803A patent/TWI752155B/zh not_active IP Right Cessation
- 2018-01-31 UY UY0001037589A patent/UY37589A/es not_active Application Discontinuation
- 2018-01-31 AR ARP180100227A patent/AR110789A1/es not_active Application Discontinuation
- 2018-02-01 MX MX2019008994A patent/MX393702B/es unknown
- 2018-02-01 JP JP2019561370A patent/JP6849823B2/ja active Active
- 2018-02-01 UA UAA201908353A patent/UA122745C2/uk unknown
- 2018-02-01 EP EP18701774.4A patent/EP3577112B1/en active Active
- 2018-02-01 AU AU2018216957A patent/AU2018216957B2/en not_active Ceased
- 2018-02-01 CR CR20190392A patent/CR20190392A/es unknown
- 2018-02-01 US US16/479,130 patent/US10981908B2/en active Active
- 2018-02-01 EA EA201991599A patent/EA038318B1/ru unknown
- 2018-02-01 WO PCT/EP2018/052542 patent/WO2018141857A1/en not_active Ceased
- 2018-02-01 CN CN201880009354.9A patent/CN110248940B/zh active Active
- 2018-02-01 CA CA3050827A patent/CA3050827C/en active Active
- 2018-02-01 ES ES18701774T patent/ES2858329T3/es active Active
- 2018-02-01 BR BR112019015716-6A patent/BR112019015716A2/pt not_active IP Right Cessation
- 2018-02-01 MY MYPI2019004031A patent/MY196831A/en unknown
- 2018-02-01 KR KR1020197023990A patent/KR102320516B1/ko not_active Expired - Fee Related
- 2018-02-01 SG SG11201906958TA patent/SG11201906958TA/en unknown
- 2018-02-01 CU CU2019000069A patent/CU20190069A7/es unknown
- 2018-02-01 PE PE2019001482A patent/PE20191478A1/es unknown
-
2019
- 2019-07-15 NI NI201900076A patent/NI201900076A/es unknown
- 2019-07-15 IL IL268080A patent/IL268080B/en unknown
- 2019-07-15 JO JOJO/P/2019/0175A patent/JOP20190175A1/ar unknown
- 2019-07-19 ZA ZA2019/04771A patent/ZA201904771B/en unknown
- 2019-07-23 CO CONC2019/0007881A patent/CO2019007881A2/es unknown
- 2019-07-24 PH PH12019550135A patent/PH12019550135A1/en unknown
- 2019-07-29 CL CL2019002108A patent/CL2019002108A1/es unknown
- 2019-07-31 EC ECSENADI201955169A patent/ECSP19055169A/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP19055169A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| UY37610A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| ECSP19055179A (es) | Compuestos moduladores del receptor de hidrocarburos de arilo (ahr) | |
| ECSP20018487A (es) | Activadores de piruvato quinasas para usar en el tratamiento de trastornos en la sangre | |
| NI201800075A (es) | Derivados de tiohidantoína sustituidos como antagonistas del receptor de andrógenos. | |
| MX2020004519A (es) | Moduladores de la vía de estrés integrada. | |
| ECSP17038999A (es) | 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139 | |
| UY36445A (es) | Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi) | |
| MX2017014956A (es) | Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares. | |
| DOP2016000212A (es) | Heterociclos condensados sustituidos como moduladores de gpr119 para el tratamiento de la diabetes, obesidad, dislipidemia y trastornos relacionados | |
| MX2017013874A (es) | Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa. | |
| UY35993A (es) | Prolinas / piperidinas sustituidas como antagonistas del receptor de orexina | |
| CO2017004074A2 (es) | Derivados de benzotiofenilo sustituido como agonistas de gpr40 para el tratamiento de la diabetes tipo ii | |
| UY36209A (es) | Derivados de la pirazina como agonistas moduladores del receptor gpr40 y composiciones farmacéuticas que los contienen | |
| MX2020006355A (es) | Pirrolidinamidas ii sustituidas. | |
| ECSP16074207A (es) | Pirazinas moduladoras de gpr6 |